​​​​​​AmeriHealth Drug Formulary updates​​

January 5, 2023

This article was updated on January 5, 2023.

​AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey (collectively, AmeriHealth New Jersey), AmeriHealth HMO, Inc. (AmeriHealth Pennsylvania), and AmeriHealth Administrators will make changes to their Select Drug Program®​​ Formulary and Value Formulary.

The changes are effective January 1, 2023, and will include:

Changes in traditional glucose monitoring supplies

  • Effective January 1, 2023, OneTouch® products will no longer be the preferred brand test strip/meters on the Select Drug Program and on the Value Formulary.
    • On the Select Drug Program, OneTouch® and all non-Contour® test strips will be non-preferred and will require prior authorization.
    • On the Value Formulary, OneTouch® and all non-Contour® test strips will be non-formulary.
  • Contour® NEXT will be the preferred brand test strip/meters and will not require prior authorization.
  • With the changes in preferred test strips, AmeriHealth New Jersey, AmeriHealth Pennsylvania, and AmeriHealth Administrators are offering a free Contour® Next One meter. The new meter can be used with the preferred brand Contour® test strips.

Changes in continuous glucose monitoring (CGM) supplies

  • Effective January 1, 2023, Freestyle Libre® products will no longer be the preferred CGM on the Select Drug Program and on the Value Formulary.
    • On the Select Drug Program, Freestyle Libre® will be non-preferred and will require prior authorization.
    • On the Value Formulary, Freestyle Libre® will be non-formulary.
  • Dexcom® products will be the preferred CGM. Prior authorization continues to be required for Dexcom.

Review the changes that go into effect January 1, 2023:

For more information on pharmacy policies and programs, visit the AmeriHealth New Jersey, AmeriHealth Pennsylvania, and AmeriHealth Administrators websites.​​​